Brezosiran vs WVE-003

Same mechanism, same race: design-graded trial evidence for both assets, with the grading rationale shown. Grades describe the quality of the evidence, never the merits of either security.

Huntington's Disease

Shared mechanism: Huntingtin (HTT) · full Huntington's Disease pipeline

Brezosiran

Developed by Regeneron Pharmaceuticals

Phase 1 in Huntington's DiseaseRNAi (siRNA)
not yet graded

No graded featured trial for this indication yet; the grade above reflects that absence, not a judgment.

Next expected readout: July 2028 · NCT06585449 (registry estimate)

No aligned efficacy figure on record for this race.

WVE-003

Developed by Wave Life Sciences

Phase 1/2 in Huntington's Diseaseoligonucleotide
Weak signal

NCT05032196 · Phase 1/2 · completed

This was a randomized, double-blind, placebo-controlled study in 47 patients, but its only primary measure was the number of patients with drug-related side effects, so it made no formal test of whether WVE-003 works. Drug-related side effects were seen in 1 of 13, 3 of 10 and 3 of 8 patients at single doses of 30, 60 and 90 mg against 2 of 16 on placebo. Its registered primary outcome on ClinicalTrials.gov is "Safety: Proportion of Patients With Treatment Emergent Adverse Events (TEAEs) Related to Study Drug". Its registered primary outcomes are safety, tolerability or dose-finding measures only, so the evidence grade is capped at weak.

Reported efficacy

Safety: Proportion of Patients With Treatment Emergent Adverse Events (TEAEs) Related to Study Drug (Day 1 through Week 24 (single ascending dose Period 1); Day 1 through Week 28 (multi dose Period 2)): Registered primary was the proportion of patients with study-drug-related TEAEs, with no formal test: single doses 30 mg 1/13, 60 mg 3/10, 90 mg 3/8 vs pooled placebo 2/16; multidose 30 mg 8/16 vs placebo 0/7 (CT.gov posted results). (not_applicable)

Result source: NCT05032196

Results for Huntington's Disease

There are not yet structured results for two selected drugs in this indication. Available results are listed below instead of an empty comparison table.

Brezosiran: no structured comparison results are available for Huntington's Disease.

Reviewed results are available, but are not yet structured for this comparison. These sourced summaries are shown separately from the aligned rows.

WVE-003
Registered primary was the proportion of patients with study-drug-related TEAEs, with no formal test: single doses 30 mg 1/13, 60 mg 3/10, 90 mg 3/8 vs pooled placebo 2/16; multidose 30 mg 8/16 vs placebo 0/7 (CT.gov posted results). NCT05032196 · Phase 1/2 · design grade: weak · reviewed ClinicalTrials.gov result

The full competitive landscape for each asset (every same-race competitor with aligned evidence, sortable) is on the asset pages: Brezosiran's landscape · WVE-003's landscape